作者
Giuseppe Giaccone, Cornelis JA Punt, Yoshitaka Ando, Rita Ruijter, Nobusuke Nishi, Marlies Peters, B Mary E Von Blomberg, Rik J Scheper, Hans JJ Van der Vliet, Alfons JM Van den Eertwegh, Marja Roelvink, Jos Beijnen, Heinz Zwierzina, Herbert M Pinedo
发表日期
2002/12/1
期刊
Clinical Cancer Research
卷号
8
期号
12
页码范围
3702-3709
出版商
American Association for Cancer Research
简介
Purpose: α-galactosylceramide (KRN7000) is a glycosphingolipid that has been shown to inhibit tumor growth and to prolong survival in inoculated mice through activation of natural killer (NK) T cells. We performed a dose escalation study of KRN7000 in advanced cancer patients.
Experimental Design: Patients with solid tumors received i.v. KRN7000 (50–4800 μg/m2) on days 1, 8, and 15 of a 4-weekly cycle. Patients were given 1 cycle and, in the absence of dose-limiting toxicity or progression, treatment was continued. Pharmacokinetics (PK) and immunomonitoring were performed in all patients.
Results: Twenty-four patients were entered into this study. No dose-limiting toxicity was observed over a wide range of doses (50–4800 μg/m2). PK was linear in the dose range tested. Immunomonitoring demonstrated that NKT cells (CD3+Vα24+Vβ11+) typically disappeared from the …
引用总数
学术搜索中的文章
G Giaccone, CJA Punt, Y Ando, R Ruijter, N Nishi… - Clinical Cancer Research, 2002
